e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Clinical tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
When do we extend the treatment of tuberculosis (TB) more than 6 months?
J. M. Garcia-Garcia, F. Alvarez-Navascues, M. Garcia-Clemente, J. Allende, J. Ferreiro, M. Martinez-Muñiz, A. Sanchez-Antuña (Aviles, Asturias, Spain)
Source:
Annual Congress 2007 - Clinical tuberculosis
Session:
Clinical tuberculosis
Session type:
Thematic Poster Session
Number:
1206
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. M. Garcia-Garcia, F. Alvarez-Navascues, M. Garcia-Clemente, J. Allende, J. Ferreiro, M. Martinez-Muñiz, A. Sanchez-Antuña (Aviles, Asturias, Spain). When do we extend the treatment of tuberculosis (TB) more than 6 months?. Eur Respir J 2007; 30: Suppl. 51, 1206
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
One year follow-up of T-SPOT. TB results in treated patients with active tuberculosis
Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease
Year: 2007
Tolerance to rifampicine (RIF) 4 months vs. isoniazid (INH) 6 months for latent tuberculosis infection (LTBI)
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis
Year: 2008
Outcomes of 6-9-12 months’ bedaquiline-containing regimens in MDR/XDR TB after 24 months follow up
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
A comparison of on-site versus remote physician follow up of directly observed preventive treatment (DOPT) for latent tuberculosis infection (LTBI) on completion rates
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II
Year: 2012
Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population
Source: Eur Respir J 2005; 26: Suppl. 49, 624s
Year: 2005
Treatment outcomes of tuberculosis patients under directly observed therapy (DOT) for three years
Source: Eur Respir J 2004; 24: Suppl. 48, 653s
Year: 2004
Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 314s
Year: 2001
Systematic review of shorter 2-3 months regimens for treatment of latent tuberculosis
Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis
Year: 2013
High completion rates with directly observed preventive treatment (DOPT) of latent tuberculosis infection (LTBI) in Ethiopian immigrants (EI) to Israel
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I
Year: 2012
Predictors of delayed smear conversion after 2 months of tuberculosis treatment
Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I
Year: 2012
What is latent tuberculosis infection (LTBI)?
Source: Annual Congress 2009 - Microbial colonisation or latency: a foot in the door to respiratory infections
Year: 2009
The role of quantiferon tuberculosis gold test (Q) in diagnosing active tuberculosis (TB) and latent tuberculosis infection (LTI) in children
Source: Annual Congress 2008 - New tests and methods to diagnose tuberculosis infection and disease and to monitor treatment
Year: 2008
Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation
Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB)
Year: 2006
Long term plasma rifampicin (R) concentrations in AIDS patients with tuberculosis (TB) under HAART therapy
Source: Eur Respir J 2003; 22: Suppl. 45, 40s
Year: 2003
Tuberculin skin test (TST) conversions rates, its relationship with interferon gamma release assay and safety and efficacy of 4 months rifampicin therapy (4R) for latent TB infection (LTBI) among nursing students in south India
Source: Annual Congress 2010 - Special treatment options in tuberculosis
Year: 2010
The efficiency of the treatment of the patients with culture-positive pulmonary tuberculosis (CPPTB) in Gdannsk, Poland in 1995 and 2000
Source: Annual Congress 2005 - Epidemiology and control of tuberculosis and LTBI
Year: 2005
Empirical treatment for tuberculosis: survey of cases treated over a period of two years
Source: Eur Respir J 2002; 20: Suppl. 38, 566s
Year: 2002
High rate of hepatitis due to treatment with pyrazinamide (PYR) and ethambutol (EMB) for latent tuberculosis infection (LTBI) in subjects exposed to MDR-TB
Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities
Year: 2005
TB re-treatment results in relapses, default and failure – cohort study for 7 years
Source: Annual Congress 2006 - Clinical epidemiology of tuberculosis
Year: 2006
Evaluation of new smear positive tuberculosis patients 5 years after initiation of treatment under a DOTS programme
Source: Annual Congress 2010 - Tuberculosis epidemiology
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept